Processing

Please wait...

Settings

Settings

1. WO2015044269 - NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS

Publication Number WO/2015/044269
Publication Date 02.04.2015
International Application No. PCT/EP2014/070489
International Filing Date 25.09.2014
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
C07D 471/04 (2006.01)
A61K 31/505 (2006.01)
CPC
C07B 2200/05
C07B 59/002
C07D 471/04
Applicants
  • JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30 B-2340 Beerse, BE
Inventors
  • HYND, George; GB
  • TISSELLI, Patrizia; GB
  • CLARK, David Edward; GB
  • KULAGOWSKI, Janusz Jozef; GB
  • MACLEOD, Calum; GB
  • MANN, Samuel Edward; GB
  • ROUSSEL, Fabien Jean Ghislain; GB
  • PRICE, Stephen Colin; GB
  • MONTANA, John Gary; GB
Priority Data
13186148.626.09.2013EP
14176125.408.07.2014EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS
(FR) NOUVEAUX DÉRIVÉS DE 3-(1BH-PYRAZOL-4-YL)-1H-PYRROLO[2,3-C]PYRIDINE EN TANT QU'INHIBITEURS DE LA NIK
Abstract
(EN)
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK -also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disordersand autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
(FR)
La présente invention concerne des agents pharmaceutiques utiles à des fins de traitement et/ou de prévention chez un mammifère, et en particulier des inhibiteurs de la kinase induisant NF-κB (NIK, également appelée MAP3K14) utiles pour traiter des maladies telles que le cancer, les troubles inflammatoires, les troubles métaboliques et les troubles auto-immuns. La présente invention concerne également des compositions pharmaceutiques comprenant de tels composés, des procédés de préparation de tels composés et compositions, et l'emploi de tels composés ou compositions pharmaceutiques dans le traitement prophylactique ou thérapeutique de maladies telles que le cancer, les troubles inflammatoires, les troubles métaboliques incluant l'obésité et le diabète, et les troubles auto-immuns.
Latest bibliographic data on file with the International Bureau